Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Bordeaux – page 87

1 156 clinical trials in Bordeaux, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Bordeaux at a glance
1 156
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 156 trials in Bordeaux

Open in trial search

Study on Brentuximab Vedotin, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Neoplasm malignant

Not recruiting

Study of Volrustomig for Patients with Advanced Solid Tumors with Mature Tertiary Lymphoid Structures

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Volrustomig
  • Sponsor:Institut Bergonie

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Pharma Mar S.A.

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Tegoprubart for Preventing Kidney Transplant Rejection in Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:At-1501
  • Sponsor:Eledon Pharmaceuticals Inc.

Pancreatic carcinoma+3

Not recruiting

Study on BI 907828 for Patients with Advanced Biliary Tract, Pancreatic, Lung, or Bladder Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dermatitis atopic

Not recruiting

Study of Upadacitinib for Adolescents and Adults with Moderate to Severe Eczema

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Migraine

Not recruiting

Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Galcanezumab
  • Sponsor:Eli Lilly & Co.

Open angle glaucoma+1

Not recruiting

Study on Long-term Safety and Effectiveness of Bimatoprost SR for Patients with Open-angle Glaucoma or Ocular Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bimatoprost
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Bordeaux

What the registry says about research in the country

01 Autoimmune & Inflammatory Conditions

Innovative research focusing on psoriatic arthritis and hidradenitis suppurativa, evaluating new therapeutic combinations and treatment strategies. Studies explore the effectiveness of targeted therapies and novel approaches like fecal microbiota transplantation.

  • Psoriatic Arthritis Treatment
  • Inflammatory Skin Conditions
  • Myasthenia Gravis Management

Clinical trials aim to improve patient outcomes through combination therapies and innovative treatment approaches.

02 Oncology Research

Comprehensive studies investigating treatments for various cancers, including head and neck squamous cell carcinoma, endometrial cancer, and bladder cancer. Research focuses on immunotherapy combinations and targeted treatments.

  • Advanced Cancer Therapies
  • Immunotherapy Approaches
  • Targeted Treatment Strategies

Trials evaluate novel drug combinations and therapeutic approaches for better cancer treatment outcomes.

03 Transplant Medicine

Ground-breaking research in kidney transplantation, focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and antibody-mediated rejection treatments.

  • Transplant Rejection Prevention
  • Immunosuppressive Therapies
  • Long-term Outcome Studies

Research aims to enhance transplant success rates and patient quality of life.

04 Neurological & Mental Health

Studies examining multiple sclerosis, narcolepsy, and major depressive disorder. Research investigates neuroinflammation patterns and innovative treatment approaches.

  • Brain Inflammation Studies
  • Sleep Disorders
  • Depression Treatment

Trials focus on understanding disease mechanisms and developing targeted therapies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.